Bifogade filer
PDF
Beskrivning
| Land | Danmark |
|---|---|
| Lista | Spotlight DK |
| Sektor | Hälsovård |
| Industri | Bioteknik |
The Company has advanced well with its planned activities
- Positive CT001 MDR assessment
- Finalization of Paediatric Safety Study 0202
- US manufacturing and launch finalization still in process
- EMA submission planning process
Cessatech A/S ("Cessatech" or the "Company") today releases its results for the period 1 January - 31 March 2025. The first quarter report is available as an attached document to this press release and on www.cessatech.com under Investor/Filings & Reports.
First quarter financial results 2025 (1 January - 31 March):
- Net Revenue was KDKK 1.243
- Operating result was KDKK -5.610
- Net result was KDKK -4296
- Cash at bank end of the period was KDKK 6.598
- Earnings per share* was KDKK -0,25
- Solidity** was 39%
*Earnings per share (DKK per share): Operating result divided by the average number of shares during the period. The total number of shares as of 31 March 2025 amounted to 17.425.094 shares, the average number of shares during the first quarter was 17.425.094
**Solidity: Total equity divided by total capital and liability
Comment from CEO, Jes Trygved:
The positive CT001 MDR assessment was a great achievement which will be part of the EMA submission, which is planned later this year hopefully after our final reporting on Study 0202 is completed. We are still spending a significant time and effort on the manufacturing and launch. preparation of CT001 for the US market, this is another major milestone, and we hope soon to have a final launch date. We are pleased to have seen good progress with the Paediatric Safety Study 0202, that has now been closed, and data cleaning and analysis is ongoing before we can present the top-line results during May. Thanks for a great effort by the team !